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1. Introduction
Hepatic bile formation and bile £ow serve many
important physiological functions. In the ¢rst place,
cholesterol is excreted from the body almost exclu-
sively via bile, either as the free compound or after
conversion to bile salts. Therefore, bile formation is
just as essential for maintaining cholesterol homeo-
stasis as dietary intake and synthesis of the sterol,
even though the latter processes have received
much more attention. Secondly, biliary bile salts, in
addition to being end-products of cholesterol catab-
olism, are essential for e⁄cient biliary cholesterol
secretion and for the solubilization of dietary fats
in the intestine. Bile £ow also has important toxico-
logical and pharmacological rami¢cations. A large
number of ‘waste products’ of endogenous origin
and xenobiotics are secreted into the bile, often after
preceding oxidative or conjugative metabolism by
hepatic phase I and phase II detoxifying systems,
respectively. For instance, the majority of bilirubin
is excreted in the form of its diglucuronide by the
biliary route, and disturbance of any step in this
process results in hyperbilirubinemia (jaundice) and
the associated clinical manifestations. Heavy metals
may serve as an example of toxic xenobiotics ex-
creted into bile.
The biochemistry of bile formation has been focus
of research in numerous laboratories, due both to its
intrinsic mechanistic interest, relevant to fundamen-
tal principles of bioenergetics and membrane bio-
chemistry, and to the serious clinical consequences
resulting from disturbances of the process, i.e., cho-
lestasis. Cholestasis, functionally de¢ned as a cessa-
tion or impairment of bile £ow, can lead to nutri-
tional problems related to malabsorption of dietary
fats and fat-soluble vitamins as well as to (irreversi-
ble) liver damage caused by accumulation of toxic
compounds. Cholestasis is a frequently observed clin-
ical condition; treatment, however, is often ham-
pered by insu⁄cient knowledge of underlying causes
and di⁄culties in distinguishing the primary events
from secondary consequences. On a mechanistic ba-
sis, cholestasis usually is divided into ‘extrahepatic’
and ‘intrahepatic’ forms. The ¢rst refers to obstruc-
tion of large bile ducts outside the liver, for instance
due to gallstones. Bile duct ligation in rodents serves
as an experimental model for this form of cholestasis.
The causes of intrahepatic cholestasis lie within the
liver, either at the level of the liver parenchymal cells,
also known as hepatocellular cholestasis, or within
the canaliculi/intrahepatic bile ductules (cholan-
gioles) and/or portal ducts. Experimental models ex-
ist for both, e.g., 17K-ethinylestradiol cholestasis [1]
for the ¢rst and sulfated glycolithocholate cholestasis
for the second form [2].
Generation of bile £ow is an osmotic process driv-
en by ongoing active secretion of solutes into the
minute bile canalicular space between adjacent liver
parenchymal cells (hepatocytes), that are sealed from
blood by tight junctions, followed by passive in£ux
of water and electrolytes by trans- or paracellular
pathways. Conceptually, the liver can therefore be
considered equivalent to a secretory epithelium,
with the canalicular membrane corresponding to
the apical membrane in a typical epithelium. Bile
salts, in quantitative terms the major organic constit-
uents of bile, are responsible for generation of the
main portion of bile £ow in most species, including
humans. This portion has been termed the bile salt-
dependent fraction of bile £ow (BSDF); the remain-
der, the bile salt-independent fraction (BSIDF), com-
prises the combined action of all other osmotically
active bile constituents. Recent data indicate that
glutathione is an important contributor to this frac-
tion, at least in the rat [3,4] (Fig. 1).
In the past couple of years it has become clear that
the cells lining the bile ducts, the cholangiocytes, sig-
ni¢cantly contribute to bile formation by (secretin-
stimulated) secretion of HCO33 and Cl
3. It has been
estimated that cholangiocyte excretion accounts for
up to 40% of human bile £ow [5,6]. In addition, the
intrahepatic bile ducts represent an important target
of injury in several disease states, such as primary
biliary cirrhosis, sclerosing cholangitis and liver
transplant rejection. For an extensive overview of
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the role of cholangiocytes in bile formation and cho-
lestasis the reader is referred to recent review articles
[7,8].
Bile salts are maintained in a so-called enterohe-
patic circulation, implying that, after being expelled
into the intestinal lumen, these compounds are e¡ec-
tively reabsorbed and transported back to the liver
via the portal system for uptake and re-secretion into
the bile. Thus, in this case, as well as in the case of
biliary secretion of other blood-bound compounds,
three consecutive transport events occur and have
to be considered: sinusoidal uptake, intracellular
transport and canalicular secretion. Kinetic analyses
have revealed that, in most cases, the canalicular
secretion step is rate-limiting for the overall process.
Therefore, canalicular transport events are thought
to constitute the molecular basis for bile production.
In the past few years, a number of important canal-
icular transport systems have been identi¢ed and
characterized (summarized in Table 1). Most canal-
icular transport systems involved in bile formation
are members of the ATP-binding cassette (ABC)
transporter superfamily [9^12]. Relevant transporters
identi¢ed so far belong either to the P-glycoprotein
(Pgp) or the multidrug resistance protein (MRP)
clusters of this superfamily [9,11]. It is now recog-
nized that absence or malfunction of speci¢c trans-
porters due to mutations in their encoding genes
underlie speci¢c, inherited forms of cholestatic liver
disease. On the other hand, the regulation of these
systems and their dysregulation as an underlying
cause of disturbed bile formation is, at the moment,
only marginally understood.
The aim of this review is to give a short overview
of inborn errors and other conditions in humans
leading to disturbed hepatobiliary transport and cho-
lestasis. In combination with observations in exper-
imental models related to these clinical states, these
will be integrated to de¢ne the current state of
knowledge about primary and secondary events in
cholestasis.
2. Inborn errors of hepatobiliary secretion
In the past couple of years considerable progress
Table 1
Properties of cloned hepatic transport proteins involved in bile
formation
Namea Species Localizationb Mr Chromosome
NTCP Human BLM 50 14q24.1^24.2
ntcp Rat BLM 51 6q24
OCT1 Human BLM 62 6q26
OATP Human BLM 80 12p12
oatp1 Rat BLM 80 ?
MDR1 Human CM 170 7q21
mdr1a Mouse CM 150 5
mdr1b Mouse CM 150 5
mdr1b Rat CM 150 4q11^12
MDR3 Human CM 170 7
mdr2 Mouse CM 150 5
mdr2 Rat CM 150 4q11^12
SPGP Human CM 170 2q24^36?
spgp Rat CM 170 ?
MRP1 Human LM 190 16p13.12^13
mrp1 Mouse LM 185 ?
mrp2 Rat CM 200 ?
MRP2 Human CM 200 10q24
MRP3 Human ? ? 17q11^12
Adapted from Ref. [9].
aSee text for full name.
bBLM, basolateral plasma membrane; CM, canalicular plasma
membrane. See http://www.med.rug.nl/mdl/tab3.htm for regu-
larly updated version.
Fig. 1. Relationship between bile £ow and biliary bile salt secre-
tion. Rats were equipped with permanent catheters in bile duct
and duodenum and both catheters were immediately connected
to each other to maintain the enterohepatic circulation. Eight
days after surgery the enterohepatic circulation was interrupted
and bile was collected in 30-min fractions, in both normal Wis-
tar and mutant GY/TR3 Wistar rats. The bile £ow at the hy-
pothetical zero value of bile salt secretion represents the bile
salt independent fraction of bile £ow. This BSIDF is decreased
in GY/TR3 rats, in part caused by reduced biliary GSH secre-
tion in these mutant rats.
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has been made in characterization and cloning of
hepatic transporters involved in bile formation, and
mutations a¡ecting their transport activity have been
identi¢ed. This knowledge has signi¢cantly contrib-
uted to our understanding of inherited cholestatic
syndromes and provides the tools for detailed anal-
ysis of regulation of transport as well as for develop-
ment of diagnostic procedures.
2.1. Bile salt transport
E⁄cient translocation of bile salts at the canalicu-
lar membrane is crucial in bile formation and main-
tenance of the BSDF. Processes involved in this im-
portant function of bile salts include their
translocation through the hepatocyte, secretion into
the bile canaliculus, reabsorption in the intestine and
uptake from the portal blood at the sinusoidal mem-
brane followed by resecretion into bile. In addition,
hepatic bile salt synthesis is required to compensate
for the small loss of bile salts via the feces to main-
tain an adequate bile salt pool size. Any disturbance
in this complex sequence of events may underlie
changes in BSDF.
2.1.1. Uptake systems
Uptake of bile salts by the hepatocytes is mediated
by the Na-taurocholate cotransporting protein
(ntcp) localized exclusively at the sinusoidal mem-
brane [13,14]. The ntcp gene contains a sequence
identical to a bile salt responsive element present in
the gene encoding cholesterol 7K-hydroxylase
(CYP7A) [15,16], the rate-limiting enzyme in the
bile salt synthesis, suggesting ntcp down-regulation
by bile salts similar to the situation observed for
CYP7A. Yet, variations in hepatic bile salt £ux rang-
ing from 0% to 300% of normal do not alter activity,
protein levels or mRNA levels of ntcp in rats [17],
indicating that this protein is constitutively expressed
under non-cholestatic conditions. The uniform zonal
distribution of ntcp [18] supports this view, since bile
salts are normally transported mainly by periportal
hepatocytes. On the other hand, ntcp is rapidly
down-regulated at transcriptional and posttranscrip-
tional level in experimental models of cholestasis,
such as bile duct ligation [19], endotoxin administra-
tion [20^22] and ethinylestradiol treatment [23]. This
down-regulation has been ascribed to accumulation
of bile salts in the hepatocytes: in fact, Gartung et al.
[24] were able to demonstrate a signi¢cant negative
correlation between plasma bile salt levels, presum-
ably re£ecting intracellular concentrations, and hep-
atic ntcp expression in rats. Similarly, ntcp is also
rapidly down-regulated in cultured hepatocytes [25]
and ntcp protein is virtually absent in hepatoma cell
lines [25,26], i.e., cells experiencing dedi¡erentiation.
Whether this down-regulation is due to bile salts that
accumulate in media of the cultured cells or to the
dedi¡erentiation-related phenomena remains to be
established. While high intracellular bile salt levels
may be important for regulation of ntcp under cho-
lestatic conditions, recent data indicate that other
factors are also involved. We were able to show
that ethinylestradiol (EE) cholestasis also leads to a
strong reduction of ntcp levels in livers of long-term
bile diverted rats (Fig. 2). Since in these rats the bile
salt pool is depleted and plasma bile salts remain
Fig. 2. Ntcp levels in liver plasma membranes isolated from
EE-treated control and 8-day bile-diverted rats. Control rats
with intact enterohepatic circulation (i) and rats with long-term
bile diversion (bd) were treated with the solvent 1,2-propanediol
(c) or with EE (ee, 5 mg/kg) for 3 days. Subsequently, blood
was collected and livers were harvested for isolation of plasma
membranes by density gradient ultracentrifugation [198]. Ap-
proximately 15 Wg of membrane protein, normalized for enrich-
ment in Na/K ATPase, was separated using sodium dodecyl
sulfate electrophoresis, transferred to nitrocellulose and probed
with anti-ntcp immunoglobulin K4, as detailed in Ref. [198].
Immune complexes were detected using horseradish peroxidase-
conjugated donkey anti-rabbit immunoglobulin G by the ECL
Western blotting kit (Amersham, Little Chalfont, UK). Plasma
bile salts were measured enzymatically. In rats with intact enter-
ohepatic circulation, EE treatment leads to a marked down-reg-
ulation of ntcp levels and to increased plasma bile salt levels
(compare lanes 1 and 2, plasma bile salt concentrations indi-
cated). After 8 days of bile diversion, the circulating bile salt
pool is exhausted and EE treatment does not increase plasma
bile salt levels; yet, ntcp levels are reduced by EE (compare
lanes 3 and 4), indicating that this e¡ect is not mediated by
bile salts.
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below detectable levels, it is highly unlikely that this
e¡ect is mediated by bile salts. Rather, it is likely that
the estrogen itself or some factor related to the oc-
currence of cholestasis per se is involved. The con-
sequences of absent or impaired ntcp activity is not
yet clear. So far, functional mutations in NTCP/ntcp
have not been reported and the generation of ntcp-
de¢cient animals is eagerly awaited for. It should be
noted that down-regulation of ntcp in EE-treated rats
[23] and in ferrochelatase-de¢cient mice (unpublished
results) is not associated with impaired biliary bile
salt secretion. This may be due to overcapacity of
the ntcp system or, alternatively, to the presence of
other systems capable of bile salt uptake. Data avail-
able so far suggest that down-regulation of ntcp is a
secondary e¡ect of cholestasis that may be aimed at
protection of the hepatocyte against the toxic actions
of high intracellular bile salt concentrations. In this
respect it is important to note that reconstitution of
bile salt transport by transfection of cDNA encoding
ntcp under the control of a cytomegalus virus in the
MC Ardle RH-7777 cell line, that normally does not
express ntcp, leads to profound structural changes
and mitochondrial abnormalities when cells were in-
cubated with physiological concentrations of bile
salts [27].
Down-regulation during extrahepatic cholestasis in
rats of the organic anion transporting polypeptide-1
(oatp1), a sodium-independent uptake system that
also accommodates bile salts, may contribute to a
decreased uptake of potential toxic bile salts in this
situation [28]. Alternatively, increased OATP mRNA
in livers of patients with chronic cholestatic liver dis-
ease and up-regulation of OATP expression in trans-
fected HepG2 cells by low concentrations of tauro-
cholate suggest that OATP may serve to enhance
sinusoidal e¥ux of toxic compounds during choles-
tasis [29], as OATP has been shown to function bi-
directionally as an anion exchanger [30].
Another important step in the maintenance of the
enterohepatic circulation of bile salts involves their
uptake from the intestine. While unconjugated bile
salt can be reabsorbed passively to a certain extent,
uptake of conjugated species is mediated by the ileal
sodium-dependent bile salt transporter (IBST/ibst)
[31,32]. In contrast to ntcp [17], ibst appears to be
regulated by physiological bile salt £ux through the
intestinal cells [33]. Patients with mutations in IBST
that a¡ect function have been described. These pa-
tients su¡er from diarrhea, steatorrhea and bile salt
malabsorption, and, as a consequence of interruption
of the enterohepatic circulation, they are thought to
have a decreased bile salt pool size [34]. Two mis-
sense mutations have been identi¢ed in one allele of
the IBST gene (also termed SLC10A2) at two con-
served amino acid positions in a family with primary
bile salt malabsorption. These mutations did not re-
sult in altered expression of the protein. Kinetic stud-
ies, however, revealed that transport of bile salts was
defective when the mutant protein was transfected
into COS cells [34]. Interestingly, ibst has also been
found in apical membranes of rat cholangiocytes, the
cells lining the hepatic bile ducts [35,36]. The phys-
iological functions of the protein at this location re-
main to be revealed. It has been suggested that its
presence enables an intrahepatic short-circuit for bili-
ary bile salts, reminiscent of the cholehepatic shunt
proposed by Ho¡man and coworkers [37,38] for un-
conjugated bile salts. A major goal in the near future
will be to establish the role of IBST in liver function
during cholestasis, a condition frequently associated
with marked bile duct proliferation.
2.1.2. Secretory systems
Functional studies in the early 1990s revealed that
there are two ATP-dependent systems involved in
bile salt transport localized in the canalicular mem-
brane [9]. The ¢rst, recently identi¢ed as MRP2/mrp2
[39^41], accommodates bivalent, i.e., sulfated and
glucuronidated bile salts, that normally comprise
only a small fraction of biliary bile salts. The other
system accommodates monovalent, amino acid con-
jugated bile salts, for experimental purposes usually
exempli¢ed by taurocholate. The nature of this latter
transporter, having a Km in the low micromolar con-
centration range, has not been clari¢ed with cer-
tainty. It has been claimed, based on in vitro work,
that the canalicular ecto-ATPase or C-CAM 105
could ful¢ll this function [42]. However, strong argu-
ments against this possibility have been put forward
[43]. Very recently, it has been claimed that a novel
member of the Pgp family, originally cloned by
Childs et al. [44], may actually be ‘the’ bile salt trans-
porter. This protein, called sister of P-glycoprotein
(SPGP/spgp), is highly abundant in rat liver and ex-
clusively present at the canalicular membrane [45,46].
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Most importantly, it has been shown in spgp-cRNA
injected oocytes and in membranes isolated from Sf9
insect cells infected with a recombinant baculovirus
containing spgp-cDNA, that spgp transports tauro-
cholate in an ATP-dependent fashion. Kinetic anal-
ysis revealed that in these systems this taurocholate
uptake is saturable with a Km value similar to that
obtained in isolated canalicular membrane vesicles
isolated from rat liver [46]. Therefore, data available
so far strongly indicate that spgp is the canalicular
bile salt transporter. At this point, genetic studies in
human cholestatic syndromes have recently provided
important clues about the nature of bile salt trans-
porting systems.
2.1.3. Progressive familial intrahepatic cholestasis
(PFIC)
From genetic studies it is now clear that PFIC, a
heterogeneous group of autosomal recessive choles-
tatic disorders characterized by severe ¢brosis, cir-
rhosis and hepatitis progressing to liver failure before
adulthood [47^52], consists of at least three di¡erent
disorders with completely separated underlying
causes. This insight has led to the proposal to distin-
guish between PFIC-1, -2 and -3. [53]. PFIC-1 and -2
appear to be associated with impaired bile salt trans-
port capacity and are characterized by low QGT val-
ues in serum [51,52]. In contrast, the defect in PFIC-
3, characterized by high QGT levels in serum, has
been pinpointed to defective phospholipid transport
into bile (see below).
The ¢rst patients identi¢ed with PFIC-1 are de-
scendants of Jacob Byler, an Amish settler from
Pennsylvania; hence the ‘old’ name Byler disease
[47]. Positional cloning studies have located the ge-
netic defect of this disease to chromosome 18q21^
q22 [54]. Interestingly, another type of inherited cho-
lestatic disease, benign recurrent intrahepatic choles-
tasis (BRIC), was mapped to the same region of
chromosome 18 [55]. In contrast to the situation in
PFIC-1, BRIC is characterized by recurrent attacks
of cholestasis separated by symptom-free periods
that may last from months to several years [56^58].
Also in contrast to PFIC-1, BRIC is not associated
with progressive liver damage [51,52,56^58]. Very re-
cent studies have provided evidence that the gene
a¡ected in PFIC-1 and BRIC (FIC 1) encodes for
a P-type ATPase, showing homology with the micro-
somal aminophospholipid translocator [59]. The gene
appears to be expressed in the liver and, surprisingly,
at an even higher level in the intestine. At the mo-
ment, the intracellular localization of the protein and
its function are completely unknown. From the clin-
ical presentation of both diseases it is likely that the
protein is somehow involved in bile salt transport. In
this respect it is important to note that the onset of
cholestasis in BRIC is characterized by rapid increase
in serum bile salt levels, before other cholestatic
markers start to deviate [60]. In addition, increased
fecal bile salt loss due to intestinal malabsorption in
non-symptomatic BRIC patients [61] is compatible
with a function of the protein in bile salt transport
in the intestine.
Patients with almost identical clinical presentation,
but unrelated to the Byler family have been referred
to as Byler syndrome. In a number of these patients,
the defect has also been mapped to chromosome 18,
suggesting a similar etiology of the disease [62,63].
Yet, Arnell et al. [64], who studied eight Swedish
families with PFIC, excluded linkage to 18q21^22,
providing evidence for genetic heterogeneity in this
disorder. Strautnieks et al. [53,65] studied six Middle
East kindreds by homozygosity mapping and con-
ventional linkage analysis, and mapped a locus for
this subgroup to chromosome 2q24. As SPGP has
recently been mapped to chromosome 2, it is attrac-
tive to speculate that the SPGP gene is a¡ected in
these patients with PFIC, now referred to as PFIC-2
and that defective canalicular bile salt transport
underlies this disease [66].
2.1.4. Inborn errors of bile salt synthesis
Disturbed de novo bile salt synthesis from choles-
terol may contribute to decreased bile formation. A
cascade of enzymatic conversions of the cholesterol
backbone leads via di¡erent pathways to the primary
bile salts cholate and chenodeoxycholate [67,68]. An
incomplete conversion by improperly functioning en-
zymes in this route can result in the formation of
toxic bile salt intermediates or bile salt metabolites
that interfere with transport processes and, as a con-
sequence, to cholestasis. At least ¢ve inborn errors of
the bile salt biosynthetic pathways have been de-
scribed [69,70].
The Smitz-Lemli-Opitz syndrome is characterized
by extremely low levels of cholesterol in the circula-
BBADIS 61757 8-10-98
N.R. Koopen et al. / Biochimica et Biophysica Acta 1408 (1998) 1^176
tion and very high concentrations of its precursor
7-dehydrocholesterol [71,72]. These patients share a
mutation in the gene encoding 7-dehydrocholesterol
7K-reductase, the last enzyme in the cholesterol
biosynthetic pathway. Drastically reduced bile salt
secretion in feces have been reported [71], indicating
reduced bile salt synthesis. Although not directly
measured to the best of our knowledge, it is
highly likely that BSDF is impaired in these pa-
tients.
Progressive liver disease and cholestatic jaundice
are seen in patients with a defect in 3L hydroxyste-
roid v5-dehydrogenase/isomerase [73^75]. The di-
and trihydroxy cholanoic acids and their sulfates
that accumulate are unable to generate BSDF and
inhibit biliary secretion of other compounds. It was
shown that these atypical bile salts act as cholestatic
agents by inhibiting the ATP-dependent transport
system for bile salts [76]. De¢ciency for 3-oxo-v4-ste-
roid 5L-reductase leads to accumulation of 3-oxo-v4-
bile salts that are extremely hepatotoxic. These un-
usual bile salts were also shown to inhibit ATP-de-
pendent bile salt transport [76]. This, together with
decreased amounts of primary bile salts that are
formed result in a decreased BSDF [77,78]. The
gene encoding the latter enzyme has been cloned
[79] and several mutations have been identi¢ed
[70,79].
Cerebrotendinous xanthomatosis is a rare lipid
storage disease [80] associated with disturbed forma-
tion of bile salts, especially of chenodeoxycholate.
Increased concentrations of so-called bile alcohols
are found in these patients [69,81]. This disease is
caused by mutations in the CYP27 gene, encoding
the mitochondrial enzyme sterol 27-hydroxylase, in-
volved in the formation of chenodeoxycholate via
both the neutral and acidic pathways of bile salt syn-
thesis. Several mutations in this gene have been iden-
ti¢ed so far [82^85]. Finally, peroxisomal disorders
are characterized by accumulation of dihydroxy and
trihydroxy coprostanoic acids and their metabolites
[86]. E¡ects of these compounds on bile formation
per se have not been reported.
In general, treatment with primary bile salts or
with ursodeoxycholic acid may be bene¢cial in these
patients, by improving the formation of BSDF and
in case of primary bile salts, by suppressing synthesis
of the atypical bile salts [87]. Yet, in the case of a
primary defect in bile salt transport, bile salt therapy
is contraindicated by de¢nition.
2.2. Phospholipid translocation
Secretion of phospholipids into bile is essential for
e⁄cient removal of the cholesterol in bile [88] and for
protection of cells lining the bile ductuli and ducts
against the actions of free (hydrophobic) bile salts.
Biliary phospholipids consist mainly of phosphatidyl-
choline with bile-speci¢c acyl-chain con¢guration
[89]. When phospholipid secretion is impaired, bile
salts may disrupt membrane structures and mem-
brane-bound enzymes appear in the circulation.
Damage of epithelial cells leads to increased levels
of QGT in the serum [90]. The mdr2 Pgp localized
in the canalicular membrane acts as an ATP-depend-
ent phosphatidylcholine translocator or ‘£ippase’
[91,92]. Mdr2 knockout mice have been generated
[88]: these animals are unable to secrete phospholi-
pids into bile. As a consequence, biliary cholesterol
secretion is also severely impaired. However, bile
£ow and biliary bile salt secretion are not a¡ected.
Consequently, these mice are not cholestatic when
the condition is de¢ned on the basis of bile £ow
alone [88]. Serum bile salt levels are increased in
these animals [88], probably re£ecting down-regula-
tion of ntcp [93]. The toxic action of bile salts at the
level of the bile ducts leads to development of char-
acteristic pathology, including bile duct proliferation
and ¢brosis. The severity of liver pathology could be
in£uenced by modulation of the hydrophobicity of
the bile salt pool in these mice. Ursodeoxycholate
largely prevented progression of disease while cho-
late, a relative hydrophobic species, aggravated liver
pathology [94].
MDR3 is the human homologue of the rodent
mdr2 [95]. Recently, inherited cholestatic liver disease
in humans has been associated with MDR3 malfunc-
tion [96^98]. This subtype of PFIC, proposed to be
termed PFIC-3, is characterized by progressive cho-
lestatic liver disease with features similar as described
for the mdr2 Pgp-de¢cient mice associated with ele-
vated QGT levels in serum [97]. In a ¢rst paper a
patient was described in which the MDR3 mRNA
could not be detected in biopsy material [97]. More
recently, analysis of genomic DNA encoding MDR3
in two PFIC patients with high QGT revealed respec-
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tively a homozygous 7 bp deletion resulting in a
frame shift, a premature stop codon and a nonsense
mutation leading to a stop codon. Resulting trun-
cated proteins may be rapidly degraded leading to
absence of immunoreactive protein in the liver [99].
2.3. Organic anion transport
Secretion of organic anions into the canalicular
lumen is mediated by an ATP-dependent organic
anion transporting protein known as cmoat or
mrp2. The human and rat genes encoding this trans-
porter have been cloned [39,100]. Rat strains lacking
mrp2 (GY/TR3 and EHBR) have generated insight
into the function of this protein [101]. These mutant
rats show defective secretion of a broad range of
organic anions including bilirubin ditaurate [101],
glutathione S-conjugates [102^105], reduced gluta-
thione [105], glucuronidated and sulfated bile salts
[106], and a variety of xenobiotics [102,107,108]. De-
spite the absence of the mrp2, some organic anion
transport activity is maintained in these rats, suggest-
ing the presence of alternative pathways for secre-
tion. Bilirubin-diglucuronide, for example, is secreted
at virtually normal rates in these mutant rats albeit
in the face of elevated serum and hepatic bilirubin
levels [101]. This may be due to the presence of an
electrogenic transporter for bilirubin diglucuronide
[109]. Other members of the ABC superfamily [110]
and more speci¢cally the mrp family [111] whose
functions are not yet known, may contribute and/
or compensate. Finally, a possible additional hepatic
transporter has been partially characterized in
functional terms but not yet sequenced [112,113].
An assessment of its relationship to known trans-
porters and its physiological role will have to await
cloning.
The nature of the mutation in mrp2 which inherits
an autosomal recessive fashion has ¢rst been ana-
lyzed in GY/TR3 rats by sequencing of the mutated
mrp2 after PCR ampli¢cation of its mRNA [39]. A
single base deletion was observed in the coding re-
gion, leading to an early stop codon and to forma-
tion of a truncated protein. In EHBR rats with a
Sprague^Dawley background, showing an identical
phenotype as Wistar GY/TR3 rats, another deletion
was recently reported [100]. The decrease in bile £ow
in these mutant rats is thought to be caused by the
decreased secretion of GSH into the bile [102]. In
contrast to older reports [114], it was recently shown
that mrp2 does mediate transport of reduced gluta-
thione in rats [105].
The recently cloned human MRP2 [41,115] is the
homologue of the canalicular mrp2 of rat liver. In
the human counterpart of the GY/TR3 rat, i.e., the
Dubin Johnson patient, MRP2 is lacking [41]. Re-
cently, mutations in MRP2 resulting in production of
a truncated MRP2-protein in Dubin Johnson pa-
tients have been identi¢ed [40]. Dubin Johnson pa-
tients show a mild conjugated hyperbilirubinemia,
but like the mutant rat, do not have severe liver
disease. Secretion of various organic anions has
been found to be impaired in these patients [116].
2.3.1. Inborn errors in bilirubin conjugation
To allow e⁄cient transport of bilirubin across at
the canalicular membrane, glucuronidation of this
poorly soluble compound is necessary. The glucuro-
nidation process is mediated by the bilirubin^UDP^
glucuronosyl transferase (B-UGT) [117,118]. Defec-
tive glucuronidation leads to accumulation of uncon-
jugated bilirubin in the liver and blood, manifesting
as jaundice. The circulating high concentrations of
unconjugated bilirubin in these patients may cause
neurological damage. Two diseases with defects in
bilirubin conjugation are known. Crigler^Najjar
type I patients lack the B-UGT caused by mutations
in the conserved region of the gene [119]. Milder
forms of this disease, type II, are characterized by
impaired activity of the enzyme. For both subtypes,
several mutations are known [117]. Patients su¡ering
Gilbert syndrome are homozygous for one additional
A in the TATAA sequence of the promoter region of
the B-UGT gene. As a result, the gene is less e⁄-
ciently transcribed, leading to a decreased expression
of the enzyme and mild hyperbilirubinemia [120].
The rat homologue for the Crigler Najjar syndrome
is the Gunn rat [121] that has a frame shift mutation
leading to the formation of a truncated, inactive pro-
tein that is rapidly degraded [122].
3. Clinical conditions associated with cholestasis
In addition to inborn errors causing cholestatic
liver disease, there is a large number of clinical con-
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ditions associated with cholestasis. In this section,
some of these common clinical conditions and exper-
imental models hereof are discussed.
3.1. Neonatal cholestasis
After birth, the neonate has to make some impor-
tant shifts in its excretory pathways. The maternal
placenta largely covers the removal of waste prod-
ucts from the fetus by speci¢c transporters in the
trophoblasts [123]. After birth, this must be taken
over by the newborn’s liver. This change requires a
certain adaptive period in which hepatic transport
systems have to be adjusted, bile salt synthesis and
bile salt pool have to be developed, and hepatic
blood £ow has to be redirected. Bile salt synthesis
and bile salt conjugation in the fetus di¡er from
those in adults as indicated by the atypical bile salts
found in meconium and urine of newborns [124^
126]. As determined in rodents, BSDF is reduced in
the neonatal state [127] and the BSIDF is completely
absent [127]. The latter is associated with a complete
absence of glutathione in bile [3,128]. This so-called
physiological cholestasis usually spontaneously dis-
appears when maturation of hepatic transport sys-
tems and bile salt metabolism has taken place. The
ontogenetic development of hepatic transport sys-
tems has been studied mainly in rats. The oatp-1
mRNA levels appears at day 16 of gestation, remains
stable until birth and then gradually increase in time
[129]. The ntcp mRNA, however, can ¢rst be de-
tected at day 20 of gestation and levels gradually
increase in time during further fetal and neonatal
life [130]. Recent studies on the developmental pat-
terns of the canalicular organic anion transporter
mrp2 and the bile salt transporter spgp showed a
similar pattern. At gestation day 18^22, levels of
mrp2 and spgp mRNA are about 2% of adult levels,
then gradually increase during gestation and the
postnatal period. Directly after birth the spgp levels
are about 160% of adult levels and decrease to adult
levels within weeks [131]. Studies on bile formation
during postnatal development shows a gradual in-
crease in both BSDF and BSIDF [127]. This is in
agreement with the levels of respective transport pro-
teins. In addition to the fact that the immaturity of
biliary transport systems and hepatic metabolism
cause physiological jaundice, it also renders the neo-
nate extremely susceptible to various cholestasis-in-
ducing factors, including total parenteral nutrition
and sepsis [132,133]. Surprisingly, however, the neo-
natal rat [134,135] and guinea pig [136,137] are ex-
tremely resistant towards the cholestatic actions of
the secondary bile salt lithocholate. The underlying
mechanism of this protection remains to be eluci-
dated.
3.2. Total parenteral nutrition
Total parenteral nutrition (TPN) is associated with
hepatic dysfunction and cholestasis in a considerable
number of patients [132,133,138]. Especially in young
infants, there is a high prevalence of TPN cholestasis.
Immaturity of the biliary system is probably an im-
portant factor contributing to hepatic problems as-
sociated with TPN in infants. Several mechanisms
have been suggested to play a role. Absence of oral
food intake and enteral stimulation a¡ects the phys-
iological stimuli for bile £ow generation and bile salt
secretion [139,140] which, together with the reduced
in£ux of bile salts from the intestine, results in a
compromised enterohepatic circulation [133]. The
composition of TPN per se has been implicated. Sol-
utions used for TPN contain glucose, amino acids
and sometimes triglycerides. Both glucose and amino
acids have been shown to decrease bile £ow in ani-
mal models [141^144]. Non-protein caloric overload
has been shown to contribute to the incidence of
cholestasis in TPN-treated patients [144^148]. Other
studies have implicated amino acids to be an impor-
tant factor in the induction of cholestasis in humans
[132,144]. In one study, the e¡ect of TPN on the
development of cholestatic jaundice was tested in
82 infants. The volume of amino acids infused was
related with the incidence of cholestasis, with the
higher relative amounts of amino acids giving a high-
er prevalence [145]. Another study pointed to a role
for speci¢c amino acids, in particular for methionine,
as potential toxic agent [144]. De¢ciencies for speci¢c
amino acids have also been proposed [132]. Since
many of the TPN solutions given are hypertonic,
TPN could give rise to cell volume regulatory re-
sponses in hepatocytes. For instance, swelling of he-
patocytes induced by hypoosmolarity of the perfu-
sate has been shown to result in increased transport
of bile salts in isolated perfused rat liver [149,150]
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while hyperosmotic pressure leads to retrieval of
mrp2 into pericanalicular vesicles in cultured hepato-
cytes [151].
Absence of intestinal stimulation during TPN
leads to overgrowth of the small intestine with colon-
ic bacteria. This enhances the intestinal production
of lithocholate from chenodeoxycholate. Lithocho-
late administration leads to cholestasis with speci¢c
liver pathology in experimental animals [152,153].
Similarities between TPN and lithocholate-induced
histological changes in the liver suggest a relationship
between the two entities [154,155]. A role of secon-
dary bile salts in the etiology of TPN cholestasis is
supported by studies demonstrating a decreased
prevalence of cholestasis in patients treated with anti-
biotics [156^158]. However, these results could not be
con¢rmed in other studies [159].
3.3. Sepsis
Hyperbilirubinemia is frequently observed in septic
patients [160^166]. Hepatic handling of the organic
anion bromosulfthalein (BSP) is altered in human
volunteers injected with endotoxin [167] and in septic
patients [166]. In the latter study, canalicular excre-
tion of the dye was found to be decreased. A reduced
hepatic BSP clearance was also found in septic ani-
mal models [165,168^170]. It was shown that the
presence of E. coli endotoxin (LPS) in the perfusate
of recirculating perfused rat livers gives rise to an
acute reduction of the biliary excretion of BSP by
36%, accompanied by a decrease in both BSIDF
and perfusate £ow [171]. Decreased glutathione se-
cretion (386%) and decreased HCO33 (325%) secre-
tion are probably responsible for this decrease in
BSIDF [171,172]. Both the basolateral uptake and
canalicular secretion of the organic anions BSP and
sulfated taurolithocholate, as measured in isolated
perfused rat livers and in isolated basolateral and
canalicular membrane vesicles from LPS-treated
rats, were reduced [20]. In the same study, it was
shown that the maximal transport rate of bile salts
was decreased by 60^80%. In basolateral membranes
isolated from LPS-treated rats, Na-dependent tau-
rocholate transport was decreased by about 40%.
ATP-Dependent bile salt transport measured in ca-
nalicular vesicles was decreased to an even greater
extent [20,22]. In both cases a decreased Vmax was
found, indicating a reduction in the number of trans-
porters available. These e¡ects of endotoxemia are
probably mediated by tumor necrosis factor K
(TNF-K) [22,173]: it was shown that the inhibition
of bile salt transport induced by endotoxin is pre-
vented, when rats are pretreated with anti-TNF-K
antibodies [173]. In addition LPS, TNF-K and inter-
leukin-1L (IL-1L) were all shown to reduce ntcp
mRNA levels [21]. IL-6 did not a¡ect ntcp mRNA,
but taurocholate uptake in IL-6 incubated hepato-
cytes was reduced [21,174]. This indicates that re-
duced basolateral bile salt uptake in this case is
caused by post-translational events. Furthermore,
the activity of Na/K-ATPase responsible for main-
tenance of a proper sodium gradient is decreased by
LPS [175], which could contribute to the decreased
bile salt uptake at the sinusoidal membrane.
Canalicular excretion of the mrp2 substrate, leuko-
triene D4 (LTD4) is reduced by 80% in the endotoxe-
mic treated rats [176]. This is also the case for bili-
rubin glucuronides [177]. Down-regulation of mrp2
activity during endotoxemia appeared to be a grad-
ual process with a maximal inhibition of 66% at 12 h
after endotoxin injection followed by a slow recovery
during the subsequent 4 to 5 days [178]. Treatment of
rats with LPS resulted in a down-regulation of the
mrp2 protein and mRNA levels [179]. Protein levels
of Pgp were not a¡ected in this study [179]. Further-
more, the inhibition of canalicular organic anion
transport during endotoxemia can be counteracted
by pretreating the animals with dexamethasone, an
established inhibitor of cytokine production [178].
LPS-Induced cytokines are also potent stimulators
of systemic and hepatic nitric oxide (NO) produc-
tion. NO donors stimulate BSIDF in rat liver [180].
In LPS-treated rats NO32 and NO
3
3 levels were in-
creased many-fold [172]. However, both stimulation
of NO synthesis with L-arginine and inhibition of
NO production by aminoguanidine did not a¡ect
bile £ow in LPS-treated rats [172], indicating that
NO itself is not involved in disturbed bile formation
during endotoxemia. If cytokines are the main medi-
ators of the down-regulation of hepatobiliary trans-
port during sepsis, this may also be of great impor-
tance for other situations were cytokines are
produced, e.g., to explain impaired hepatobiliary
transport in transplanted livers or in liver diseases
like hepatitis and primary biliary cirrhosis.
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3.4. Cholestasis of pregnancy
Intrahepatic cholestasis of pregnancy (ICP) is
characterized by pruritus in the second half of preg-
nancy, sometimes associated with elevated serum bil-
irubin and transaminases [181^185]. These symp-
toms generally disappear within a few hours to
days after delivery. A geographic variation, with
high incidences in Sweden and Chile, suggest a ge-
netic component to be involved [182,184]. This dis-
ease has been related to high perinatal mortality,
high incidence of meconium staining, abnormal in-
trapartum heart rate and preterm deliveries [181,185].
Patients susceptible for ICP often also develop cho-
lestasis during the use of oral contraceptives [182].
The actual mechanism causing ICP, however, has
not been revealed yet. Genetic studies provide evi-
dence that it is transmitted as dominant trait which
is sex-limited [183]. However, males from families
with a history of ICP show a decreased biliary secre-
tion of BSP [186]. This suggests that males can also
transmit this trait to their female descendants [186].
The increased frequency of ICP in mothers of
patients with PFIC and BRIC [47,52,99,187] sug-
gests that heterozygotes for mutations in transport
systems involved in these diseases remain asympto-
matic under normal circumstances, but cannot deal
with increased pressure on these systems induced
by pregnancy-related factors, e.g., elevated estrogen
levels. Data available so far therefore suggest
that mutations in di¡erent canalicular transport
proteins and/or regulatory proteins may underlie
ICP. Additionally, altered metabolism of estrogens
leading to formation of cholestatic metabolites can
not be excluded [188]. The observations that slight
elevations of serum bilirubin are present in 20%
of normal pregnancies and that the secretion of
BSP in EE-treated healthy volunteers is decreased,
suggest that estrogens may also modulate canalicular
secretion under ‘physiological’ circumstances [186,
189].
Administration of EE to rodents is commonly
used as a model for estrogen-related cholestasis.
EE-treatment of rats mainly a¡ects BSIDF as well
as the maximum secretory rate for taurocholate into
bile [1,190^192]. Decreased £uidity of the sinusoidal
membrane, decreased Na/K-ATPase activity and
increased permeability of the tight junctions have
been proposed as potential mechanisms [193^196].
More recently, it was shown that Na dependent
sinusoidal transport and ATP-dependent canalicular
transport of taurocholate in membrane vesicles iso-
lated from EE-treated rats are decreased [197]. Pro-
tein content and mRNA levels of ntcp were clearly
decreased by EE [23]. Both in rats and humans the
maximal secretion rate of BSP is decreased by EE
[179,186,197]. In rats this is associated with de-
creased protein levels of mrp2 [179]. The mrp2
mRNA levels were not a¡ected in EE-treated rats,
indicating posttranscriptional regulation [179]. We
recently showed in mrp2-de¢cient GY/TR3 rats
that alternative pathways for biliary secretion of or-
ganic anions, including DBSP and bilirubin diglucur-
onide, are also a¡ected by EE, resulting in severe
hyperbilirubinemia in GY/TR3 rats upon EE treat-
ment. This ¢nding shows that EE exaggerates symp-
toms in situations in which canalicular transport is
already a¡ected [198]. Besides canalicular organic
anion transport, this could also be the case for other
canalicular transport proteins such as spgp. It was
shown that the transport maximum for both tauro-
cholate and the organic anion BSP is decreased in
neonatal rats born from mothers that underwent bile
duct ligation during pregnancy [199]. This again
underlines the fact that special care has to be taken
with children when maternal cholestasis occurs dur-
ing pregnancy.
4. Cholestasis, causes and consequences
The mechanisms that underlie development of cho-
lestasis in patients can be extremely varied. In its
most simple form, mechanical obstruction of the bili-
ary tree due to gallstones or hepatic or biliary tumors
causes stagnation of bile £ow. In the newly identi¢ed
inborn errors in bile formation, for example in PFIC-
1 to -3, dysfunction of a crucial protein underlies
impaired bile formation. At the other end of the
spectrum, a complex interaction between subtle im-
pairment of transport function, accumulation of sub-
strates and/or their metabolites, damage to hepato-
cytes and subsequent in£ammation may give rise to a
vicious cycle leading to cessation of bile £ow. In this
situation, it is extremely di⁄cult to distinguish pri-
mary events from secondary consequences. Yet, this
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distinction can be crucial for designing optimal treat-
ment for the patient.
In animal models, a decrease in bile £ow is, in
general, associated with elevated cholestatic serum
markers, altered liver histology and changes in sinus-
oidal and canalicular transport as determined in vivo
and in vitro systems. The regulation of hepatic trans-
port systems in cholestatic states has been and will be
a major focus of research. However, a clear distinc-
tion between the mechanisms that actually cause cho-
lestasis and the cascade of changes that is the result
of cholestasis is also di⁄cult to make in most exper-
imental systems, including the model of bile duct
ligation and recently generated knockout mice. For
instance, extrahepatic cholestasis induced by bile
duct ligation in rats causes bile duct proliferation,
mitochondrial dysfunction, disruption of tight junc-
tion structure and redistribution of membrane pro-
teins [200^207]. In addition, down-regulation of ca-
nalicular ABC transporters and of sinusoidal
transporters like ntcp and oatp-1 occurs [19,179]
and serum bile salts, bilirubin and transaminases in-
crease. These changes are clearly secondary to induc-
tion of cholestasis. A number of these e¡ects are also
seen in intrahepatic cholestasis induced by EE. Yet,
in this case, down-regulation of ntcp [23] and mrp2
[179] have been implicated in the onset of cholestasis.
In our hands, administration of EE (5 mg/kg) for 3
consecutive days caused a 30% decrease in bile £ow
but did not, or only minimally, a¡ect the serum
markers of cholestasis in normal rats. However,
even with this treatment schedule we found reduced
mrp2 levels in the canalicular membrane and reduced
biliary GSH secretion rates. In the same study, we
found a very similar decrease in bile £ow in GY/TR3
rats that do not express mrp2 and do not secrete
GSH into bile [198]. This example illustrates that a
reduction of bile £ow can be established without
changes serum markers and that down-regulation
of transporters are not always the cause of cholesta-
sis but often a consequence. The down-regulation of
ntcp in a number of cholestatic models probably
provides a protective mechanism for the hepatocytes
against intracellular accumulation of bile salts. Re-
versibly, serum bile salt levels and transaminases are
increased and ntcp protein content and activity is
decreased in mdr2-knock out mice, while bile £ow
is actually stimulated in these animals (Koopen et
al., unpublished results). An even more striking ex-
ample hereof is provided by ferrochelatase-de¢cient
mice with de¢cient heme synthesis [208,209]. In these
mice, we recently found an 80-fold increase in serum
bile salts, increased transaminases and bilirubin and
an almost complete absence of ntcp protein in the
liver. Paradoxically, bile £ow and biliary bile salt
secretion in these animals are not decreased but in-
creased. These ¢ndings illustrate very clearly that
there may be di¡erences between ‘clinical cholestasis’
diagnosed on the basis of serum values of bile salts,
bilirubin and transaminases and ‘actual’ cholestasis,
as de¢ned by reduced bile £ow. In this particular
model, proliferation of bile ducts may modulate
bile formation at non-hepatocytic level [7]. Clearly,
more research is needed to clarify the relationships
between transporter activities, transporter localiza-
tion (membranous versus vesicular) and the actual
process of bile formation.
In conclusion, therefore, the identi¢cation and
cloning of a number of key proteins involved in bili-
ary transport, and the description of common muta-
tions herein, provide tools to diagnose the primary
event in certain types of inherited cholestatic syn-
dromes and allow for development of adequate treat-
ment. For other, acquired types of cholestasis, treat-
ment remains limited to palliative interventions until
the real causes are de¢ned.
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